SC
SLN

Shay Capital’s Silence Therapeutics SLN Stock Holding History

Shay Capital’s Portfolio SLN Stock Details SLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-47,728
Closed -$135K – 420
2025
Q1 		$135K Buy
+47,728
New +$233K 0.02% 262
2024
Q2 		– Sell
-15,150
Closed -$327K – 416
2024
Q1 		$327K Buy
+15,150
New +$329K 0.05% 238

Other funds holding SLN

TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
LOAMU
Lombard Odier Asset Management (USA) New York $957M AUM 35.8% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
CF
Cantor Fitzgerald New York $6.78B AUM 29.01% 1-Year Est. Return

Shay Capital's SLN Position: Q2 2025 in Review

Shay Capital sold out of Silence Therapeutics (SLN) in Q2 2025, closing a stake of 47,728 shares — an estimated $135K sold.

Shay Capital first reported a position in SLN in Q1 2024 and held it in 2 quarters. The position peaked at $327K in Q1 2024. 55 funds tracked by Wall St. Rank hold SLN as of Q2 2025.

  • Shay Capital reported no remaining Silence Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Shay Capital sold 47,728 Silence Therapeutics shares in Q2 2025, an estimated $135K.
  • Shay Capital first reported a position in Silence Therapeutics in Q1 2024 and held it in 2 quarters.
  • Shay Capital's Silence Therapeutics position peaked at $327K in Q1 2024.
  • 55 funds tracked by Wall St. Rank held Silence Therapeutics as of Q2 2025.

Based on Shay Capital's 13F filing for Q2 2025, filed 14 Aug 2025.